Carolin Isabella Kurz

Dr. Carolin Isabella Kurz

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2021 in Neuropathology and Applied Neurobiology
Verified
Journal Article
Open access
PDF file
CKCarolin Isabella Kurz
Carolin Isabella Kurz
LWLauren Walker
Lauren Walker
BRBoris‐Stephan Rauchmann
Boris‐Stephan Rauchmann
RPRobert Perneczky
Robert Perneczky
The pathological processes leading to synapse loss, neuronal loss, brain atrophy and gliosis in Alzheimer's disease (AD) and their relation to vascular disease and immunological changes are yet to be fully explored. Amyloid‐β (Aβ) aggregation, vascular damage and altered immune response interact at the blood–brain barrier (BBB), affecting the brain endothelium and fuelling neurodegeneration. The aim of the present systematic literature review was to critically appraise and to summarise the published evidence on the clinical correlations and pathophysiological concepts of BBB damage in AD, focusing on human data. The PubMed, Cochrane, Medline and Embase databases were searched for original research articles, systematic reviews and meta‐analyses, published in English language from 01/2000 to 07/2021, using the keywords Alzheimer*, amyloid‐β or β‐amyloid or abeta and BBB. This review shows that specific changes of intercellular structures, reduced expression of transendothelial carriers, induction of vasoactive mediators and activation of both astroglia and monocytes/macrophages characterise BBB damage in human AD and AD models. BBB dysfunction on magnetic resonance imaging takes place early in the disease course in AD‐specific brain regions. The toxic effects of Aβ and apolipoprotein E (ApoE) are likely to induce a non‐cerebral‐amyloid‐angiopathy‐related degeneration of endothelial cells, independently of cerebrovascular disease; however, some of the observed structural changes may just arise with age. Small vessel disease, ApoE, loss of pericytes, proinflammatory signalling and cerebral amyloid angiopathy enhance BBB damage. Novel therapeutic approaches for AD, including magnetic resonance‐guided focused ultrasound, aim to open the BBB, potentially leading to an improved drainage of Aβ along perivascular channels and increased elimination from the brain. In vitro treatments with ApoE‐modifying agents yielded promising effects on modulating BBB function. Reducing cardiovascular risk factors represents one of the most promising interventions for dementia prevention at present. However, further research is needed to elucidate the connection of BBB damage and tau pathology, the role of proinflammatory mediators in draining macromolecules and cells from the cerebral parenchyma, including their contribution to cerebral amyloid angiopathy. Improved insight into these pathomechanisms may allow to shed light on the role of Aβ deposition as a primary versus a secondary event in the complex pathogenesis of AD.

14 November 2016 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
CKCarolin Isabella Kurz
Carolin Isabella Kurz
GEGeorg Ebersbach
Georg Ebersbach
GRGesine Respondek
Gesine Respondek
AGArmin Giese
Armin Giese
TAThomas Arzberger
Thomas Arzberger
GHGünter U. Höglinger
Günter U. Höglinger
Postural instability and supranuclear gaze palsy represent the key symptoms of Richardson’s syndrome, the most frequent clinical manifestation of progressive supranuclear palsy (PSP). However, a proportion of PSP patients never develops ocular motor symptoms, which prevents clinicians from establishing the diagnosis during lifetime according to current diagnostic criteria. We present one instructive autopsy-confirmed PSP case with prospective video-documented clinical course, showing striking temporal divergence of initially present postural instability and delayed development of ocular motor dysfunction. Brain imaging and autopsy findings were typical of PSP, but the temporal sequence of symptoms was unusual with isolated postural instability predominating the clinical course for many years and slowing of vertical saccades/supranuclear gaze palsy evolving not until the 9th/11th year after disease onset. Although other differential diagnoses were unlikely, this patient did not pass the threshold for possible or probable diagnosis of PSP according to current diagnostic criteria until very late in the disease course. This first well documented, autopsy confirmed case of PSP with predominant postural instability further expands the clinical spectrum of PSP and points out the need of new clinical diagnostic criteria with sufficient sensitivity and specificity for an early and reliable diagnosis.

8 August 2025 in Nature Communications
Verified
Journal Article
Open access
CMCarolin Meyer
Carolin Meyer
TNTheresa Niedermeier
Theresa Niedermeier
PFPaul L. C. Feyen
Paul L. C. Feyen
FSFelix Strübing
Felix Strübing
BRBoris-Stephan Rauchmann
Boris-Stephan Rauchmann
LPLars Paeger
Lars Paeger
Alzheimer’s disease (AD) often begins with non-cognitive symptoms such as olfactory deficits, which can predict later cognitive decline, though the mechanisms remain unclear. Pathologically, the brainstem locus coeruleus (LC), the main source of the neurotransmitter noradrenalin (NA) modulating olfactory information processing is affected early. Here we show early and distinct loss of noradrenergic input to the olfactory bulb (OB) coinciding with impaired olfaction in an AD mouse model, before appearance of amyloid plaques. Mechanistically, OB microglia recognize and phagocytose LC axons. Reducing phagocytosis genetically preserves LC axons and olfaction. Prodromal AD patients display elevated TSPO-PET signals in the OB, similarly to App NL-G-F mice. We further confirm early LC axon degeneration in post-mortem OBs in patients with early AD. Our findings reveal a mechanism linking early LC damage to hyposmia in AD, suggesting olfactory testing and neurocircuit imaging for early diagnosis and enable timely therapeutic intervention for Alzheimer’s disease.

2 May 2025 in European Archives of Psychiatry and Clinical Neuroscience
Verified
Journal Article
Open access
PDF file
CKCarolin Isabella Kurz
Carolin Isabella Kurz
LCLaura Carli
Laura Carli
SGSelim Üstün Gürsel
Selim Üstün Gürsel
ISIsabelle Schrurs
Isabelle Schrurs
AJAlexander Jethwa
Alexander Jethwa
RPRobert Perneczky
Robert Perneczky
Background: Blood-based biomarkers (BBBMs) could significantly facilitate the diagnosis of Alzheimer’s disease (AD) and non-AD dementia by providing less invasive alternatives to cerebrospinal fluid (CSF) and positron emission tomography (PET) imaging. Objective: This study investigated how well the BBBMs—amyloid-β (Aβ) 1-42/1-40 ratio, phosphorylated tau181 (pTau181), apolipoprotein E4 (ApoE4), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL)—reflect thorough clinical work-up validated by PET and CSF biomarkers in participants with AD (n = 27), Aβ-negative CBS (n = 26), and agematched healthy controls (HC) (n = 17). Methods: Factor and correlation explored biomarker associations. Bayesian regression, backward selection regression, and ROC curve analysis were applied to identify optimal biomarker combinations and diagnostic cut-offs. Results: In AD cases, pTau181 and ApoE4 levels were elevated, and the Aβ1-42/1-40 ratio was reduced. ROC analysis showed high accuracy for pTau181, ApoE4 and Aβ1-42/1-40 in discriminating AD from HC, with a combination significantly improving performance. However, limited fold change, and high variability reduced the diagnostic applicability of Aβ1-42/1-40 ratio. Elevated NfL levels were the most reliable biomarker for CBS-Aβ(–) cases. GFAP showed limited discriminatory power due to overlapping levels, suggesting that it may not serve as a disease-specific biomarker but may be indicative of general neurodegeneration. Conclusions: This study highlights the diagnostic utility of pTau181, ApoE4 and the Aβ1-42/1-40 ratio for AD and NfL in the CBS-Aβ(–) cases and emphasizes the added value of combined biomarker models for group differentiation. Prospective studies will help validate these findings and refine clinical thresholds.

30 July 2025 in Journal of Public Health Research
Verified
Journal Article
Open access
CKCarolin Isabella Kurz
Carolin Isabella Kurz
IAIlir Alimehmeti
Ilir Alimehmeti
MBMarina Boban
Marina Boban
SKSmiljana Kostic
Smiljana Kostic
OSOsman Sinanovic
Osman Sinanovic
AKAlexander Kurz
Alexander Kurz
Dementia is a growing challenge in Southeastern and Western Europe, with aging trends projected to accelerate in the former region. The region is facing critical gaps in dementia care due to rural-urban disparities, workforce shortages, and limited access to specialized services. Widespread reliance on informal caregiving and underdeveloped diagnostic infrastructure delay early diagnosis and equitable access to the healthcare system. This perspective article presents sustainable, regionally tailored solutions and innovative strategies from a multinational dementia network, which are aimed at improving care outcomes through collaboration, capacity building, and digital innovation. Tailored workshops and multilingual platforms have raised awareness and encouraged innovative care approaches. Meanwhile, mobile memory teams in underserved areas have been shown to enhance caregiver support and patient outcomes. The Circle of Care Hub framework was developed to bridge coordination gaps and promote equitable, integrated dementia care by linking healthcare providers, social workers, and families. Digital tools have been piloted to enhance professional training, interdisciplinary collaboration, and informal carer support. Addressing barriers such as limited services and workforce shortages is essential for sustainable improvements. Future initiatives should prioritize scalable interventions, such as mobile teams, digital platforms with evaluation mechanisms, and hybrid care models, while investing in early diagnosis, dementia centers and region-specific prevention strategies informed by robust epidemiological data. Achieving sustainable dementia care requires a combination of digital innovation and community-based solutions.

28 March 2026 in The Journal Of Prevention of Alzheimer's Disease
Verified
Journal Article
Open access
ACArda C. Cetindag
Arda C. Cetindag
CSCarola G. Schipke
Carola G. Schipke
HEHermann Esselmann
Hermann Esselmann
NKNiels Kruse
Niels Kruse
JWJens Wiltfang
Jens Wiltfang
OPOliver Peters
Oliver Peters
Early and accurate detection of Alzheimer's disease (AD) is essential for timely intervention and development of disease-modifying treatments. The DZNE-Longitudinal Cognitive Impairment and Dementia Study (DELCODE) provides a deeply phenotyped cohort covering preclinical and early clinical stages, including subjective cognitive decline (SCD) and mild cognitive impairment (MCI). Astrocyte reactivity and its biomarkers, particularly glial fibrillary acidic protein (GFAP), have gained increasing attention in AD research; however, the relationship between GFAP and amyloid in early disease, as well as its potential prognostic value beyond its association with amyloid status, remains insufficiently understood. To evaluate the performance of CSF and plasma GFAP across early disease stages, compare these measures according to amyloid status, and assess the prognostic value of GFAP for clinical progression across diagnostic stages during longitudinal follow-up. This study used data from the multicenter DELCODE cohort in Germany, including participants with available plasma and/or CSF samples and standardized clinical, cognitive, imaging, and biomarker assessments. GFAP concentrations in plasma and CSF were quantified using validated immunoassay platforms. Standard CSF AD biomarkers and ApoE genotype were measured using established assays. Amyloid status was defined by the CSF Aβ42/40 ratio. Longitudinal follow-up occurred annually for up to ∼10 years, with clinical conversion determined according to NIA-AA criteria. Plasma and CSF GFAP increased across the AD continuum, with higher levels in MCI and AD (p < 0.001). Plasma GFAP showed a stronger association with amyloid status than CSF GFAP across all groups. In MCI, plasma GFAP combined with age and ApoE4 yielded an AUC of 0.87. Elevated plasma GFAP predicted increased risk of conversion to MCI (HR = 2.19, p < 0.001; adjusted HR = 1.70, p = 0.0056) and AD dementia (HR = 3.5; adjusted HR = 2.49 both p < 0.001). Plasma GFAP is a sensitive, minimally invasive biomarker with diagnostic relevance for amyloid detection and prognostic relevance for clinical progression in early AD.